Based on reports of NF-κB constitutive activation in numerous hematologic malignancies [12] and solid tumors, including breast and prostate tumors, melanoma and pancreatic cancer [13, 14], a role for NF-κB is now well established in multiple aspects of cancer development, progression, and treatment resistance [15]. This evidence concerns the gene NFKB1 and melanoma.